Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 5th International Pituitary congress - abstract book (1998)

Detailed reference viewed: 4 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Acta Neurochirurgica (1995), 133

Detailed reference viewed: 1 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 3rd International pituitary congress - Abstract book (1993)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Journal of Endocrinological Investigation (1993), 16(1-8), 137

Detailed reference viewed: 1 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly : does it improve surgical cure rate?
Stevenaert, Achille ULg; Lenelle, Jacques ULg; Martin, Didier ULg et al

in 10th European Congress of Neurosurgery - Abstract book (1995)

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly.
Stevenaert, Achille ULg; Harris, A. G.; Kovacs, K. et al

in Metabolism : Clinical and Experimental (1992), 41(9 Suppl. 2), 51-8

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered ... [more ▼]

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered for 3 to 6 weeks before surgery in 12 patients and for 4 to 39 months in 25 patients. The clinical response was judged as excellent or good in 10 of 12 patients from group I and in 23 of 25 patients from group II. Marked reduction (ie, greater than 50% of initial values) in serum growth hormone (GH) levels was seen in all patients, with levels to less than 5 micrograms/L in 68% of patients and less than 2 micrograms/L in 27%. Insulin-like growth factor 1 (IGF-1) levels decreased to within normal limits in half the cases. During long-term treatment, an escape phenomenon could be seen. Varying degrees of tumor shrinkage were seen in more than 50% of cases. During surgery, with regard to the relative ease or difficulty in removing the tumor, the consistency of the tumor and the separation of normal from pathological tissue, no significant difference was observed between patients given octreotide and those from control series. Morphological changes in adenomatous tissue were rather small. The surgical outcome was similar in the pretreated series as in the control series, except in enclosed adenomas, which showed a tendency to a higher success rate. Since octreotide improves both the clinical condition and hormonal parameters and induces varying degrees of tumor shrinkage, it is potentially useful as an adjunct to surgery. Morphological data suggest that octreotide exercises a functional inhibitory effect on GH release. [less ▲]

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailPresurgical Octreotide: Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Metabolism : Clinical and Experimental (1996), 45(8 Suppl. 1), 72-4

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 micrograms octreotide subcutaneously three ... [more ▼]

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 micrograms octreotide subcutaneously three times daily: for 3 to 6 weeks before surgery in 14 patients (group 1); and for 3 to 9 months in 41 and for 13 to 39 months in nine (n = 50, group 2). In 18 group 2 patients, the dose was increased stepwise to 500 micrograms three times daily because of incomplete suppression of growth hormone (GH)/insulin-like growth factor-1 (IGF-1). Tumor shrinkage was seen in 60% within 3 weeks, being nearly maximal by 3 to 4 months. More group 2 patients had greater than 25% tumor shrinkage (14 of 48 v 1 of 14 in group 1). Clinical response was excellent or good in 89%. Decrease in soft-tissue swelling and weight loss, and improved vitality, performance, carbohydrate metabolism, and cardiovascular function, facilitated anesthetic and surgical management; tumor removal was easy in virtually all cases. In all 64 patients, GH levels decreased by > or = 50%, and to < 2 micrograms/L in three of 14 patients initially and 25 of 50 patients after more prolonged treatment. IGF-1 levels decreased to normal in seven of 14 group 1 and 31 of 50 group 2 patients. Light and electron microscopy showed that adenomatous tissue exposed to octreotide had lysosomal accumulation, amyloid deposition, mild to moderate perivascular fibrosis, and moderate size reduction in both cytoplasmic and nuclear areas, with virtually no cellular complications. Remission with enclosed adenomas was greater (p < .05) than for the 108 patients not treated with octreotide; there was no difference for invasive adenomas. Octreotide use for 3 to 4 months before surgery can be recommended. [less ▲]

Detailed reference viewed: 33 (1 ULg)
See detailPresurgical Sandostatin treatment in acromegaly.
Stevenaert, Achille ULg; Beckers, Albert ULg

Conference (1991)

Detailed reference viewed: 3 (0 ULg)
Full Text
See detailPrêt public et droit d’auteur : le "droit de prêt", c’est pour bientôt
Habrand, Tanguy ULg

Article for general public (2006)

Detailed reference viewed: 8 (2 ULg)
See detailLe prétendu séisme de Tongres vers 600 : une invention hagiographique
Alexandre, Pierre ULg

in Ciel et Terre (1989), 105

Detailed reference viewed: 12 (1 ULg)
Full Text
See detailPrétest, suivi et contrôle de la performance des produits nouveaux
Choffray, Jean-Marie ULg

in P. Joffre et Y. Simon (Ed.) Encyclopédie des Sciences de Gestion (1999)

L’objet de cet article est de présenter un ensemble cohérent de concepts et de modèles utiles en matière de prétest, de suivi et de contrôle de la performance d’un produit nouveau. L’approche suivie est ... [more ▼]

L’objet de cet article est de présenter un ensemble cohérent de concepts et de modèles utiles en matière de prétest, de suivi et de contrôle de la performance d’un produit nouveau. L’approche suivie est résolument modulaire, orientée-objet, de telle sorte que le lecteur puisse construire son propre système à partir du problème auquel il est confronté: évaluation pré-lancement, suivi en phase d’introduction et de croissance, et contrôle du marketing-mix au cours de l’étape de développement du marché. Le kit proposé rassemble les modèles de diffusion, les modèles d’intensité de réachat, les fonctions de réponse et l’analyse dynamique des coûts. Ces outils conservent leur pertinence quel que soit le couple produit-marché considéré: grande consommation, durable, industriel et/ou service. [less ▲]

Detailed reference viewed: 224 (31 ULg)
Peer Reviewed
See detailPretherapeutic assessment of cerebral aneuvrysms with arterially enhanced spiral CT
Vanderschelden, P.; Flandroy, P.; Dondelinger, Robert ULg et al

Conference (1995, November 26)

Detailed reference viewed: 3 (0 ULg)
Full Text
See detailPrétraitement de données en reconnaissance de formes par RNA
Schyns, Michael ULg

Master's dissertation (1993)

Les réseaux de neurones n'ont malheureusement pas que des avantages. Leur taille croît avec la quantité et la complexité des données à traiter. Or le principal inconvénient du RNA est lié à sa complexité ... [more ▼]

Les réseaux de neurones n'ont malheureusement pas que des avantages. Leur taille croît avec la quantité et la complexité des données à traiter. Or le principal inconvénient du RNA est lié à sa complexité. Plus elle est grande, plus le RNA sera difficile et coûteux à implémenter physiquement et plus son temps d'apprentissage sera grand. Pour résoudre ce problème, une solution est de prétraiter les données pour diminuer leur taille. Il nous a dès lors été demandé d'analyser trois méthodes de compression applicables au traitement par RNA : la méthode de Karhunen-Loève, la méthode LPC (Linear Predictive Coding) et la méthode NLPCA (Non Linear Principal Composant Analysis). Nous en avons ajouté une : la méthode LSP (Line Spectral Pair). Les chapitres qui y sont consacrés tenteront de convaincre le lecteur de l'efficacité de ces procédés. Nous déterminerons également comment choisir la méthode à utiliser pour un problème de classification posé à un RNA. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailPretransplant helper T-lymphocyte determination in bone marrow donors: acute graft-versus-host disease prediction and relation with long-term survival
Winandy, Marie ULg; Lewalle, Philippe; Deneys, Véronique et al

in British Journal of Haematology (1999), 105

Helper T-lymphocyte precursor (HTLp) frequency from 19 allogeneic bone marrow donors was tested to detect weak antigenic differences with the recipient, and then compared to the outcome. HTLp frequency ... [more ▼]

Helper T-lymphocyte precursor (HTLp) frequency from 19 allogeneic bone marrow donors was tested to detect weak antigenic differences with the recipient, and then compared to the outcome. HTLp frequency was estimated in limiting dilution cultures, and HLA-DR and CD 80 expression by stimulating cells was measured by flow cytometry. 12/19 patients experienced acute graft-versus-host disease (aGVHD) grade II–IV. A good correlation was found between high pretransplant HTLp frequency and grade II–IV aGVHD (median: 1/55848 PBMNC for II–IV GVHD versus 1/ 184346 for 0–I GVHD; P¼0·008). Sensitivity was 82%, specificity 63%, negative predictive value 71% and positive predictive value 75%. Long-term survivors also had a lower HTLp median frequency (1/143354) when compared with patients who died as a result of the transplant procedure (1/22100, P < 0·001). No correlation was found between HTLp frequency and HLA-DR or CD80 expression by patient’s cells. We conclude that HTLp frequency estimation can predict, although poorly, acute GVHD risk and long-term survival. [less ▲]

Detailed reference viewed: 11 (0 ULg)